KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Bristol Myers Squibb (BMY) over the last 17 years, with Q4 2025 value amounting to $10.2 billion.

  • Bristol Myers Squibb's Cash & Equivalents fell 132.42% to $10.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $10.2 billion, marking a year-over-year decrease of 132.42%. This contributed to the annual value of $10.2 billion for FY2025, which is 132.42% down from last year.
  • According to the latest figures from Q4 2025, Bristol Myers Squibb's Cash & Equivalents is $10.2 billion, which was down 132.42% from $15.7 billion recorded in Q3 2025.
  • Bristol Myers Squibb's Cash & Equivalents' 5-year high stood at $15.7 billion during Q3 2025, with a 5-year trough of $6.3 billion in Q2 2024.
  • Over the past 5 years, Bristol Myers Squibb's median Cash & Equivalents value was $10.5 billion (recorded in 2022), while the average stood at $10.5 billion.
  • In the last 5 years, Bristol Myers Squibb's Cash & Equivalents crashed by 4469.75% in 2021 and then surged by 10020.66% in 2025.
  • Quarter analysis of 5 years shows Bristol Myers Squibb's Cash & Equivalents stood at $14.0 billion in 2021, then plummeted by 34.74% to $9.1 billion in 2022, then increased by 25.66% to $11.5 billion in 2023, then fell by 9.75% to $10.3 billion in 2024, then dropped by 1.32% to $10.2 billion in 2025.
  • Its last three reported values are $10.2 billion in Q4 2025, $15.7 billion for Q3 2025, and $12.6 billion during Q2 2025.